Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Defense Threat Reduction Agency (DTRA) of the Department of Defense (DoD) has granted $1.6m to Cleveland BioLabs to fund additional research on pharmacodynamic profile of CBLB502.
Subscribe to our email newsletter
CBLB502 is said to a bioengineered derivative of a microbial protein that helps in reducing injury from acute stresses, such as radiation and chemotherapy.
Cleveland BioLabs Public Health and Government Services senior vice president Michelle Ross said they are very excited about expanding their working relationship with DTRA, and the DoD as a whole.
"There is currently no Food and Drug Administration (FDA) approved countermeasure for exposure to total body irradiation and the research sponsored by this contract supports our collaborative efforts to advance CBLB502 towards a Biologic License Application (BLA) to fulfill this unmet need," Ross said.